Phaseline

Companies › Roche

Roche: clinical trials, targets and expected readouts

107 active drug programs in 852 registered trials: 464 Phase 2, 199 Phase 1, 158 Phase 3, 31 Phase 4; Oncology, Neurology, Ophthalmology, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Risdiplam (RO7034067)
SMN2 pre-mRNA positive modulator
SMN2Phase 4Muscular Atrophy, Spinal; Spinal Muscular Atrophy (SMA)Nov 2026
Emicizumab
Coagulation factor IX and X other
F9, F10Phase 4Severe Hemophilia A; Von Willebrand Disease, Type 3; Factor VIII Deficiency, Congenital; Hemophilia A Patient …Nov 2026
Faricimab
Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor
ANGPT2, VEGFAPhase 4Diabetic Macular EdemaJan 2027
Ocrelizumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 4Relapsing Multiple Sclerosis; Progressive Multiple Sclerosis (PMS); Multiple Sclerosis; Multiple Sclerosis, Primary Progressive …Sep 2027
Faricimab
Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor
ANGPT2, VEGFAPhase 4Neovascular Age-related Macular Degeneration (nAMD); Wet Age-related Macular Degeneration; Diabetic Macular Edema; Macular Degeneration Choroidal Neovascularization …Sep 2027
Ocrelizumab (rHuPH20)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 4Multiple SclerosisFeb 2029
Atezolizumab
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 3Non-Small Cell Lung Cancer; Hepatocellular Carcinoma; Muscle-invasive Bladder Cancer; Unresectable Hepatocellular Carcinoma …Nov 2026
Tiragolumab
T-cell immunoreceptor with Ig and ITIM domains inhibitor
TIGITPhase 3Hepatocellular Carcinoma; Cancer; Renal Cell Carcinoma; Rectal Neoplasms …Nov 2026
Inavolisib
PI3-kinase p110-alpha subunit inhibitor
PIK3CAPhase 3Breast Cancer; Metastatic Breast Cancer; Metastatic Castration-Resistant Prostate Cancer; PIK3CA-Mutated Cancers …Nov 2026
Satralizumab
IL6Ralpha/GP130 antagonist
IL6R, IL6STPhase 3NMDAR Autoimmune Encephalitis; Neuromyelitis Optica Spectrum Disorder; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Duchenne Muscular Dystrophy …Nov 2026
Afimkibart
Anti-integrin α4β7 monoclonal antibody
ITGA4, ITGB7, IL22RA1Phase 3Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis …Dec 2026
Crovalimab
Complement C5 inhibitor
C5Phase 3Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic SyndromeJan 2027
Alectinib
ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor
ALK, RET, EML4Phase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors …Jan 2027
Entrectinib (RXDX-101)
Neurotrophic tyrosine kinase receptor inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ALK tyrosine kinase receptor inhibitor
NTRK1, NTRK2, NTRK3, ROS1, ALKPhase 3Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Breast Cancer; Solid Tumors …Jan 2027
Glofitamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma …Jan 2027
Ranibizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Neovascular Age-related Macular Degeneration (nAMD); Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Neovascular Age-Related Macular Degeneration …Feb 2027
Cevostamab
BCMA-directed bispecific antibody
BCMAPhase 3Multiple MyelomaFeb 2027
Mosunetuzumab
T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent
CD3E, CD3G, CD3D, MS4A1Phase 3Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma …Feb 2027
Polatuzumab vedotin
B-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhibitor
CD79B, TubulinPhase 3Non-Hodgkin Lymphoma; Large B-Cell Lymphoma; B-cell Non-Hodgkin Lymphoma; Non-Hodgkins Lymphoma …Feb 2027
Pertuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Solid TumorsMar 2027
Trastuzumab Emtansine
Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 3Breast Cancer; Ovarian Cancer; Metastatic Solid Tumor; Early Breast Cancer …Mar 2027
Enicepatide (RO7795068)
Dual GLP-1/GIP receptor agonist
GLP1R, GIPRPhase 3Obesity; Obesity or Overweight; Healthy ParticipantsApr 2027
Baloxavir marboxil
Polymerase acidic protein inhibitor
INFLAV, PB2Phase 3Influenza, Human; Influenza; Influenza Disease; Flu; Hematopoietic and Lymphoid Cell NeoplasmApr 2027
Fenebrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Relapsing Multiple Sclerosis; Multiple Sclerosis, Primary ProgressiveJun 2027
Giredestrant
Estrogen receptor alpha degrader
ESR1Phase 3Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer; Breast CancerJun 2027
Astegolimab
IL-33 receptor (ST2) inhibitor
IL1RAP, IL33RPhase 3Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary DiseaseJun 2027
Bevacizumab
Vascular endothelial growth factor A inhibitor
VEGFAPhase 3Hepatocellular Carcinoma; Advanced Liver CancersJul 2027
Giredestrant
Estrogen receptor alpha degrader
ESR1Phase 3Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer; Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Early Breast Cancer …Jul 2027
NXT007
Factor VIII mimetic/extended half-life factor VIII replacement
F8Phase 3Hemophilia ASep 2027
Obinutuzumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Childhood Idiopathic Nephrotic Syndrome; Primary Membranous Nephropathy; Systemic Lupus Erythematosus; Lupus Nephritis …Dec 2027
Trontinemab
Anti-tau antibody targeting phosphorylated tau
MAPTPhase 3Alzheimers Disease; Alzheimer's DiseaseFeb 2028
Ipatasertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Cancer; Ovarian Cancer; Solid Tumors; Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer …Feb 2028
Lurbinectedin
DNA alkylating agent
–Phase 3Small-Cell Lung CancerFeb 2028
Sefaxersen (RO7434656)
Antisense Oligonucleotide (ASO) therapy
–Phase 3Primary IgA NephropathyMay 2028
Pegozafermin (BIO89-100)–Phase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With FibrosisJun 2028
Petrelintide
Dual GLP-1 and glucagon receptor agonist
GLP1R, GCGRPhase 3Obesity or OverweightOct 2028
Divarasib
KRAS G12C inhibitor
KRASPhase 3Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Colorectal CancerNov 2028
Prasinezumab
Alpha-synuclein binding agent
SNCAPhase 3Parkinson's Disease; Parkinsons DiseaseJun 2029
Lenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Relapsed or Refractory Follicular Lymphoma; Follicular LymphomaDec 2029
Mycophenolate Mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 3Childhood Idiopathic Nephrotic Syndrome–
Sorafenib
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 3Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma …–
RO7204239
Anti-myostatin antibody
MSTNPhase 2Facioscapulohumeral Muscular Dystrophy (FSHD); Spinal Muscular Atrophy (SMA); Obesity; Type 2 Diabetes MellitusNov 2026
RO7269162
BACE1 inhibitor
APPPhase 2Alzheimer's DiseaseNov 2026
Cobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Non-small Cell Lung Cancer; Melanoma; Metastatic Distal Bile Duct Adenocarcinoma; Chronic Myelomonocytic Leukemia (CMML) …Nov 2026
Pralsetinib
Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
RET, CCDC6, KIF5BPhase 2Non-small Cell Lung Cancer; Advanced Thyroid Cancer Patients Who Received Target Therapy; Lung Cancer Stage IIINov 2026
Vemurafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 2Non-small Cell Lung Cancer; Thyroid Gland Follicular Carcinoma; Colorectal Carcinoma; Hairy Cell Leukemia …Nov 2026
RO7795081
GLP-1/GIP receptor dual agonist
GIPR, GLP1RPhase 2Type 2 Diabetes Mellitus; Overweight; Healthy Volunteers; Renal ImpairmentDec 2026
Tobemstomig–Phase 2Renal Cell Carcinoma; Breast Cancer; Urothelial Cancer; Advanced Liver CancersDec 2026
Cobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Non-Small Cell Lung Cancer; Ovarian CancerJun 2027
Trastuzumab Emtansine
Receptor protein-tyrosine kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 2Neoplasm MetastasisJun 2027
RO7837195–Phase 2Ulcerative ColitisAug 2027
Autogene Cevumeran
TLR3 agonist
TLR3Phase 2Muscle-invasive Urothelial CarcinomaNov 2027
Selnoflast
selective NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome inhibito
–Phase 2AtherosclerosisJan 2028
Enzalutamide
Androgen Receptor antagonist
ARPhase 2Metastatic Castration-Resistant Prostate CancerMar 2028
RO7268489–Phase 2Progressive Multiple SclerosisMay 2028
RO7771950
HER2 tyrosine kinase inhibitor
–Phase 2HER2-positive Breast CancerMay 2029
RO7568282
BACE inhibitor
–Phase 2Alzheimer's DiseaseNov 2029
RO7965032
unclear - complement C3 inhibitor
–Phase 2Geographic Atrophy Secondary to Age-Related Macular DegenerationAug 2030
Autogene cevumeran
Personalized neoantigen vaccine
–Phase 2Adenocarcinoma, Pancreatic DuctalJan 2031
OpRegen
Retinal pigment epithelium cell therapy
–Phase 2Geographic AtrophyMar 2031
Tominersen
Huntingtin mRNA antisense inhibitor
HTTPhase 2Huntington Disease–
RO7497372–Phase 1Diabetic Macular EdemaNov 2026
Cevostamab–Phase 1Multiple Myeloma; Relapsed or Refractory Multiple Myeloma; Lupus Erythematosus, SystemicNov 2026
XmAb24306
Bispecific antibody
–Phase 1Multiple MyelomaNov 2026
RG6496–Phase 1Huntington's DiseaseDec 2026
RO7790121
anti-LOXL2 monoclonal antibody
–Phase 1MASHDec 2026
Belvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Melanoma; Primary Brain TumorDec 2026
Englumafusp alfa
CD19-targeted 4-1BB ligand
CD19, TNFSF14Phase 1Lymphoma, Non-HodgkinMar 2027
RO7812653–Phase 1Alzheimer's DiseaseMar 2027
Runimotamab
HER2-targeting bispecific antibody
ERBB2Phase 1Solid TumorsApr 2027
RO7806881–Phase 1Healthy VolunteersMay 2027
RO7567132–Phase 1Cancer-NeoplasmsMay 2027
RO7890597–Phase 1Healthy VolunteersJun 2027
RO7247669
Anti-PD-1 and anti-LAG-3 bispecific antibody
PDCD1, LAG3Phase 1Solid TumorsJun 2027
RO7656594–Phase 1Advanced Prostate CancerJun 2027
RO7121932
S1P1 receptor modulator
–Phase 1Multiple SclerosisJul 2027
TPST-1120
TPS inhibitor
–Phase 1Advanced Liver CancersJul 2027
Tocilizumab
Interleukin-6 receptor alpha subunit inhibitor
IL6RPhase 1Advanced Liver Cancers; Takayasu Arteritis; Primary Cutaneous Amyloidosis; Giant Cell Arteritis …Jul 2027
RO7126209
Anti-amyloid beta monoclonal antibody
APPPhase 1Alzheimers DiseaseJul 2027
ZN-A-1041–Phase 1Advanced Solid TumorsAug 2027
GDC-1261–Phase 1Advanced Prostate CancerNov 2027
RO7507062–Phase 1Systemic Lupus ErythematosusNov 2027
GDC-1971–Phase 1Non-Small Cell Lung CancerDec 2027
GDC-6036
KRAS G12C inhibitor
KRASPhase 1Non-Small Cell Lung CancerDec 2027
RO7663498
unclear - Roche code-named drug
–Phase 1Diabetic RetinopathyJan 2028
RO7566802–Phase 1Locally Advanced Solid TumorsMar 2028
GDC-7035
KRAS G12D inhibitor
KRASPhase 1Solid TumorMay 2028
Enzelkitug–Phase 1Locally Advanced or Metastatic Solid TumorsJul 2028
Iberdomide (CC-220)
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 1Multiple Myeloma; Non-Hodgkin LymphomaJul 2028
GDC-4198
FGFR1 inhibitor
FGFR1Phase 1Breast CancerAug 2028
RO7673396
RAS inhibitor
–Phase 1NeoplasmsAug 2028
RO7830698–Phase 1Chronic Obstructive Pulmonary Disease (COPD)Oct 2028
RO7823653–Phase 1Diabetic Macular EdemaNov 2028
RO7875913–Phase 1Healthy VolunteersJun 2030
RO7851624
anti-TACSTD2 (TROP-2) antibody-drug conjugate
TACSTD2Phase 1Relapsed/Refractory Multiple MyelomaJul 2030
SY-5609–Phase 1Metastatic Colorectal CancerAug 2030
Ladiratuzumab Vedotin
Tubulin inhibitor; Zinc transporter ZIP6 binding agent
Tubulin, SLC39A6Phase 1Metastatic Breast CancerSep 2030
Selicrelumab
Tumor necrosis factor receptor superfamily member 5 agonist
CD40Phase 1Metastatic Breast CancerSep 2030
OpRegen
Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells
–Phase 1Age-Related Macular DegenerationJan 2031
SPK-8011QQ (RO7878488)
Gene therapy for Factor VIII deficiency
F8Phase 1Hemophilia AApr 2032
P-CD19CD20-ALLO1
allogeneic CAR-T cell therapy targeting CD19 and CD20
CD19, CD20Phase 1Multiple SclerosisAug 2032
203Pb-DOTAM (RO7205834-009)
Lead-203 labeled imaging surrogate for dosimetry assessment
–Phase 1Metastatic Colorectal CancerFeb 2034
212Pb-DOTAM (RO7205834-010)
Lead-212 labeled therapeutic radioligand for alpha-particle therapy
–Phase 1Metastatic Colorectal CancerFeb 2034
SPLIT Abs (RO7782304, RO7782306)
CEA-targeting pretargeting antibody for radioimmunotherapy
CEACAM5Phase 1Metastatic Colorectal CancerFeb 2034
SPK-10001
Gene therapy targeting huntingtin gene
HTTPhase 1Huntington DiseaseJan 2035
GDC-6988
Unclear - code-named drug
–Phase 1Non-cystic Fibrosis Bronchiectasis–
RO7763505–Phase 1Stable Coronary Artery Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03179943AtezolizumabPhase 2Urothelial CarcinomaOncologyJul 2020
NCT04650321OcrelizumabPhase 4Multiple SclerosisNeurologyAug 2021
NCT04300686TocilizumabPhase 4Takayasu ArteritisImmunologyMay 2022
NCT03879577Trastuzumab EmtansinePhase 2Breast CancerOncologyMar 2023
NCT04941287AtezolizumabPhase 2Metastatic Distal Bile Duct AdenocarcinomaOncologyJan 2024
NCT04941287CobimetinibPhase 2Metastatic Distal Bile Duct AdenocarcinomaOncologyJan 2024
NCT02486718AtezolizumabPhase 3Non-Small Cell Lung CancerOncologyJan 2024
NCT03671018MosunetuzumabPhase 1B-cell Non-Hodgkin LymphomaOncologyJan 2024
NCT03671018Polatuzumab vedotinPhase 1B-cell Non-Hodgkin LymphomaOncologyJan 2024
NCT04563338AtezolizumabPhase 2Hepatocellular CarcinomaOncologyJun 2024
NCT04367311AtezolizumabPhase 2Lung CancerOncologyAug 2024
NCT05751343AtezolizumabPhase 2Hepatocellular CarcinomaOncologyAug 2024
NCT03385655IpatasertibPhase 2Prostate CancerOncologyOct 2024
NCT04980222GlofitamabPhase 2LymphomaOncologyOct 2024
NCT06482086SorafenibPhase 2Locally Advanced Thyroid Gland CarcinomaOncologyDec 2024
NCT04888221TocilizumabPhase 3Giant Cell ArteritisImmunologyJan 2025
NCT04387734OcrelizumabPhase 4Relapsing Multiple SclerosisNeurologyFeb 2025
NCT04166721AtezolizumabPhase 1Metastatic Esophageal CancerOncologyMar 2025
NCT06875245FaricimabPhase 4Wet Age-related Macular DegenerationOphthalmologyApr 2025
NCT05548556RO7204239Phase 2Facioscapulohumeral Muscular Dystrophy (FSHD)NeurologyMay 2025
NCT05904886AtezolizumabPhase 3Hepatocellular CarcinomaOncologyMay 2025
NCT05904886TiragolumabPhase 3Hepatocellular CarcinomaOncologyMay 2025
NCT05904886BevacizumabPhase 3Hepatocellular CarcinomaOncologyMay 2025
NCT05781308AtezolizumabPhase 2Non Small Cell Lung CancerOncologyJun 2025
NCT04660344AtezolizumabPhase 3Muscle-invasive Bladder CancerOncologyJun 2025
NCT04289779AtezolizumabPhase 2Bladder CancerOncologyJun 2025
NCT04479267Polatuzumab vedotinPhase 2Diffuse Large B-Cell LymphomaOncologyJun 2025
NCT05595642AstegolimabPhase 3Chronic Obstructive Pulmonary Disease (COPD)RespiratoryJun 2025
NCT05350592TocilizumabPhase 2Acute Myocardial InfarctionCardiovascularJun 2025
NCT05627557ObinutuzumabPhase 3Childhood Idiopathic Nephrotic SyndromeGenitourinarySep 2025
NCT05627557Mycophenolate MofetilPhase 3Childhood Idiopathic Nephrotic SyndromeGenitourinarySep 2025
NCT04020809AtezolizumabPhase 1Cutaneous MelanomaOncologyOct 2025
NCT06998875TocilizumabPhase 4Primary Cutaneous AmyloidosisMetabolic and endocrineOct 2025
NCT05174650AtezolizumabPhase 2Intrahepatic CholangiocarcinomaOncologyDec 2025
NCT05067348TocilizumabPhase 2Myasthenia Gravis, GeneralizedNeurologyDec 2025
NCT03899428SorafenibPhase 2Hepatocellular CarcinomaOncologyDec 2025
NCT04680442Trastuzumab EmtansinePhase 2Breast CancerOncologyDec 2025
NCT06452537TocilizumabPhase 2Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseNeurologyJan 2026
NCT04409639CobimetinibPhase 2Chronic Myelomonocytic Leukemia (CMML)OncologyJan 2026
NCT07439055EmicizumabPhase 2Hemophilia A PatientHematologyMar 2026
NCT05689671AtezolizumabPhase 4Non-Small Cell Lung Cancer MetastaticOncologyMar 2026
NCT05992220AtezolizumabPhase 2Hepatocellular CarcinomaOncologyMar 2026
NCT03673787AtezolizumabPhase 1Solid TumorOncologyMar 2026
NCT03673787IpatasertibPhase 1Solid TumorOncologyMar 2026
NCT05686551TominersenPhase 2Huntington DiseaseNeurologyMay 2026
NCT06952452RanibizumabPhase 3Wet Age-related Macular DegenerationOphthalmologyJul 2026
NCT06603246GDC-6988Phase 1Non-cystic Fibrosis BronchiectasisRespiratoryAug 2026
NCT07285850AtezolizumabPhase 2HCC - Hepatocellular CarcinomaOncologyAug 2026
NCT05498896AtezolizumabPhase 2Triple Negative Breast CancerOncologyAug 2026
NCT05498896IpatasertibPhase 2Triple Negative Breast CancerOncologyAug 2026
NCT05092373AtezolizumabPhase 1Advanced Breast CarcinomaOncologySep 2026
NCT05805501TiragolumabPhase 2Renal Cell CarcinomaOncologyOct 2026
NCT05805501TobemstomigPhase 2Renal Cell CarcinomaOncologyOct 2026
NCT04770896AtezolizumabPhase 3Unresectable Hepatocellular CarcinomaOncologyOct 2026
NCT04770896SorafenibPhase 3Unresectable Hepatocellular CarcinomaOncologyOct 2026
NCT05852691TobemstomigPhase 2Breast CancerOncologyOct 2026
NCT06426160TocilizumabPhase 2Pancreatitis, ChronicGastroenterologyOct 2026
NCT03533283AtezolizumabPhase 1Non-Hodgkins LymphomaOncologyOct 2026
NCT03523858OcrelizumabPhase 3Progressive Multiple Sclerosis (PMS)NeurologyOct 2026
NCT03533283GlofitamabPhase 1Non-Hodgkins LymphomaOncologyOct 2026

The 60 nearest readouts of 852 trials; the rest in the app.

From the company's SEC filings

Complete response letters from FDA

Targets

MS4A1 (5) ERBB2 (4) Tubulin (4) VEGFA (4) GLP1R (3) BRAF (3) KRAS (3) HTT (2) ALK (2) RET (2) GIPR (2) CD3E (2)

Companies with the same targets

Pfizer Eli Lilly Beijing Biotech Novo Nordisk Novartis AbbVie AstraZeneca Shanghai Henlius Biotech Jiangsu HengRui Medicine Regeneron Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.